



Biographies

- [Prof. Ewa JANKOWSKA, Poland](#)
- [Prof. John McMURRAY, United Kingdom](#)
- [Dr Claudia KAISER-ALBERS, Germany](#)
- [Dr Tomas ANDERSSON, Sweden](#)
- [Prof. Biykem BOZKURT, USA](#)
- [Dr Robert CALIFF, USA](#)
- [Dr Ovidiu CHIONCEL, Romania](#)
- [Prof. Andrew COATS, United Kingdom,](#)
- [Prof. Martin COWIE, United Kingdom,](#)
- [Prof. Alexandra GONCALVES, USA](#)
- [Dr Loreena HILL, United Kingdom,](#)
- [Prof. Friedrich KOEHLER, Germany](#)
- [Prof. Lars LUND, Sweden](#)
- [Prof. Theresa McDONAGH, United Kingdom,](#)
- [Prof. Marco METRA, Italy](#)
- [Dr Clemens MITTMANN, Germany](#)
- [Prof. Uwe SIEBERT, Austria](#)
- [Prof. Scott SOLOMON, USA](#)
- [Prof. Maurizio VOLTERRANI, Italy](#)



Prof. Ewa JANKOWSKA

Prof. Ewa A. Jankowska, MD PhD, FESC, FHFA

Prof. Ewa A. Jankowska is currently Professor of Medicine and Head of Department of Translational Cardiology and Clinical Registries, Institute of Heart Diseases, Wrocław Medical University and University Hospital in Wrocław, Poland. She is a specialist in internal diseases, cardiology and geriatrics. She has been trained in Wrocław Medical University and in Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London.

She has contributed to the establishment of the ESC community of young cardiologists. She has also been a co-founder and previous co-ordinator of the Heart failure specialists Of Tomorrow (HoT) initiative within the HFA ESC.

Prof. Jankowska is a member of the HFA ESC Board (since 2016) (currently as a treasurer). She has served as a chairperson or a member of several HFA committees (e.g. the Committee on Online Education and Digital Health, the Study Group on Frailty, Cachexia and Sarcopenia). She has been a co-director the HFA Clinical Trialists Summer School (editions: 2017, 2018 and 2019) and is a current co-director of the HFA Course on Clinical Trials in Heart Failure 2021. She has been a member of the Task Force on the ESC HFA Atlas Programme in Europe.

Prof. Jankowska has been a member of the Task Force for 2016 and 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure as well as the Task Force for 2021 ESC Guidelines for cardiovascular prevention.

She is currently a member of the Board of the Association of Heart Failure of Polish Cardiac Society. She is a co-founder and volunteer of the Foundation Supporting Seniors in Poland.

Prof Jankowska's primary clinical and research interests are:



- 1) peripheral pathomechanisms in the progression of heart failure, including cardiorespiratory reflex control and hormone derangements (catabolic/anabolic imbalance, androgen/oestrogen imbalance);
- 2) co-morbidities in heart failure, including cardiorenal anaemia syndrome and iron deficiency;
- 3) the role of skeletal muscles and exercise training in heart failure;
- 4) acute heart failure;
- 5) male ageing, andropause, frailty syndrome;
- 6) methodology of clinical research and clinical trials in cardiovascular medicine.

She has been a major investigator in 9 Polish research grants and 5 European projects. She has served as a co-PI in the AFFIRM-AHF trial.



Prof. John McMurray

John McMurray, BSC (Hons), MB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FMedSci, OBE

Prof McMurray is currently Professor of Medical Cardiology and Deputy Director (Clinical) of the Institute of Cardiovascular and Medical Sciences and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.

Prof McMurray's primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials. He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including CHARM-Added, EMPHASIS-HF, PARADIGM-HF, Harmony-Outcomes, PARAGON-HF, DAPA-HF and DAPA-CKD.

Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women's Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011.

He is a Past-President of the Heart Failure Association of the ESC.

He is a Highly Cited Researcher (<https://recognition.webofsciencegroup.com/awards/highly-cited/2019/>) and has a H-index of 200 (<https://scholar.google.com/citations?user=n0ZdRMoAAAAJ&hl=en>).

He is and has been involved in many guideline committees, including chairing the Task Force for 2011/2012 ESC Guidelines on Heart Failure. Professor McMurray is also a member of the editorial board of several journals including the European Journal of Heart Failure, Diabetes Care and the New England Journal of Medicine, Senior Consulting Editor for JACC-Heart Failure and Guest Editor for Circulation & Circulation: Heart Failure.

He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University,



Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases).

Prof McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognises outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition.

Professor McMurray was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”.



Dr Claudia KAISER-ALBERS, MSD

Claudia Kaiser-Albers (MD/PhD) is a Clinical Director in Global Clinical Development at MSD (MERCK in the US and Canada).

Claudia started her research career studying underlying biomedical and molecular mechanisms of LVAD therapy in the Molecular Biology Lab at the Heart Center NRW in Germany.

She subsequently developed her expertise in inflammatory processes during her post-doctoral training in Chicago, IL, triggering a clinical career in Neurology with a neurovascular and neuroimmunology focus after her board certifications.

Claudia joined MSD Clinical Development in 2017 and has since then supported several clinical programs through various phases of development, mainly in cardiovascular, but also other therapeutic areas.



**Dr Tomas LG ANDERSSON,
AstraZeneca**

Tomas LG Andersson, Vice President – Clinical Cardiovascular Late Stage Development, AstraZeneca

Tomas Andersson, MD PhD, is a physician specialized in Clinical Pharmacology with cardiovascular focus, with more than 20 years experience from Pharmaceutical industry.

Dr Andersson has a long-standing interest and expertise of cardiovascular and respiratory late phase drug development. He has led several clinical drug projects from design until registrational approval globally.

He is also interested in developing new ways of conducting clinical research and making Cardiovascular drug development more efficient and sustainable.

Dr Andersson leads a global group of physicians and scientists with responsibility of designing and developing the clinical programs for late phase cardiovascular assets in AstraZeneca.



Prof. Biykem BOZKURT

Prof. Biykem Bozkurt is an advanced heart failure and cardiac transplantation cardiologist at Baylor College of Medicine in Houston Texas, where she serves as the Associate Provost of Faculty Affairs and Senior Associate Dean of Faculty Development, Cain Chair in Cardiology and Professor of Medicine.

She is the Immediate Past President of the Heart Failure Society of America.

She has been identified as one of Web of Science's top 1% Highly Cited Researchers.

She serves as a Senior Associate Editor for Circulation; HF Section Editor for the JACC, and Co-Chair of the 20201 AHA/ACC Heart Failure Guidelines Writing Committee.



Dr Robert Califf

Dr Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health for Verily and Google Health.

Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke's center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology.

He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017.

A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine.

Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.



Dr Ovidiu CHIONCEL

Dr Ovidiu Chioncel received his medical degree from the University of Medicine and Pharmacy Carol Davila, Bucharest in 1992, and earned his PhD in 2012.

He received training in Medical Statistics (Medical Statistics and Clinical Trials, University of Leuven UZG, Belgium-1998), Echocardiography (Istituto Clinico Humanitas Milan, Italy-1999), advanced Heart Failure therapies (Universitat Klinikum Munster, Germany-2001), special echo techniques and CardioCT (Cardiocentro Ticino Switzerland-2006) and Heart Transplant and Ventricular Assist Devices (Sheba Medical Center, Israel -2013).

Since 2014 he is leading ICCU and Cardiology 1st Department at Institute of Emergency for Cardiovascular Diseases, C.C.Iliescu, Bucharest, Romania. Dr Chioncel is Professor of Cardiology at University of Medicine Carol Davila, Bucharest.

His major clinical and research interests are related to Heart Failure, Cardiac Imaging and Emergency Medicine. He is Director of Romanian Acute Heart Failure Syndrome registry (RO-AHFS), National Registry of Acute Aortic Dissections (RENADA) and National Coordinator of EORP ESC-HF registries. He is author of three monographies dedicated to Heart Failure and more than 90 chapters in cardiovascular textbooks. He authored more than 170 manuscripts in peer reviewed journals.

Dr Chioncel is Member of ESC/HFA Board, Member of Executive Committee, Coordinator of Acute Heart Failure Committee, Chairperson of National Heart Failure Societies and Member of ESC-EORP Oversight Committee. Since 2020, Dr Chioncel is President Elect of Romanian Society of Cardiology.

He served as member of the seven Steering Committees / Executive Committees / Adjudication Committees for phase III clinical trials and country coordinator for ten clinical trials in the field of cardiovascular medicine.



Prof. Andrew COATS

Prof. Andrew Coats was born in Melbourne, Australia and studied Medicine at Oxford and Cambridge.

He has published over 20 patents and more than 1500 publications (including 2 theses, 15 Government reports, 10 full text books, and over 750 peer-reviewed full papers) and has more than 110,000 career citations, and a personal H-index of 140 (ISI Web of Science, 31/3/2021). He has been ranked the top academic cardiologist in the Asia-Pacific region and third outside North America by Microsoft Academic Rankings, and named in the top 1000 cited researchers in history by Google scholar citations (<http://www.webometrics.info/en/hlargerthan100>).

He served as Editor-in-Chief of the International Journal of Cardiology from 1999 to 2016 and has served on more than 10 major journal editorial boards. Andrew is an expert on heart failure. He first described the Muscle Hypothesis of Chronic Heart Failure that explained dyspnoea and exaggerated ventilatory responses in CHF patients. He first described chemoreflex overactivity in CHF and periodic breathing and published the first ever randomised trial of exercise training for CHF.

Andrew has been Chairman or Committee member of the following major Cardiovascular and Cancer Cachexia Clinical Trials: CHRISTMAS, CHARM, COPERNICUS, OXAM, OPTIMAAL, OVERTURE, REPLACE, SENIORS, AUGMENT-HF and ACT-ONE. He has served Head of Cardiology at Imperial College and Director of Cardiology at Royal Brompton Hospital, London then as Dean of Medicine and Deputy Vice-President at the University of Sydney, and as Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. He is presently President of the Heart Failure Association of the ESC.



Prof. Martin COWIE

Professor Martin R Cowie, MD, MSc (Epid), FRCP, FRCP (Ed), FESC, FHFA, FACC

Professor of Cardiology, King's College London (Royal Brompton Hospital), UK

m.cowie@imperial.ac.uk @ProfMartinCowie

Martin Cowie is Consultant Cardiologist at the Royal Brompton Hospital, London (a Division of Guy's & St Thomas'), where he leads the heart failure service, and Professor in the School of Cardiovascular Medicine & Sciences at King's College London. He was a Non-Executive Director and Board member of the National Institute for Health and Care Excellence (NICE) from 2016-2020.

Professor Cowie's research interests focus on health technology assessment and delivery of efficient and effective care for patients with heart failure, with a focus on diagnostics, drugs, or devices. He also has had a longstanding interest in evaluating remote monitoring and now digital technologies in heart failure.

Professor Cowie is a founding member and past-Chairman of the British Society for Heart Failure, in addition to being a Fellow of the American College of Cardiology, and the European Society of Cardiology (ESC). He chairs the Digital Health Committee of the ESC. Professor Cowie was shortlisted for the NHS Digital Champion (Leadership) Award in England in 2017, was awarded the Thomas Lewis Medal for services to British Cardiology in 2019, and was the recipient of the Roy Award from the UK Heart Failure Patient Charity, Pumping Marvellous, in 2019 for outstanding contribution to excellence in heart failure.

Professor Cowie is an Associate Editor of Heart and Journal of the American College of Cardiology-Heart Failure, and is an editorial board member of many other journals.

He has contributed chapters to many books, and has written a book for patients entitled "Living with Heart Failure – A Guide for Patients".



He has published 350+ Pub-Med listed papers, and has a current h-index of 80, with his work cited more than 80 000 times in the scientific literature.

He particularly enjoys speaking to members of the public about cardiovascular health issues, and has spoken at the Cambridge Science Festival, The Wellcome Foundation, The Dana Foundation, and most recently delivered a TEDx talk on “Beating the World’s Biggest Killer”, which you can view on https://www.youtube.com/watch?v=t_Xp65OUtU0

He has spoken at countless scientific meetings all around the world – and enjoys interacting with any audience.



Prof. Alexandra GONCALVES

Prof. Alexandra Goncalves is the Philips Chief Medical Officer, Strategy, M&A and Partnerships, a position she has held since June 2019.

As an academic cardiologist with a business acumen, she provides functional leadership for clinical innovation and clinical strategy for Philips. Alexandra works closely and collaboratively with business, research and functional leaders across the organization, as well as exploring inorganic growth opportunities.

Alexandra has joined Philips in 2016 and worked three years as Sr. Medical Director for the Ultrasound business. She was instrumental for the Cardiovascular Ultrasound business success by leading the evaluation of medical trends, by providing clinical insights and strategic direction, and by developing impactful partnerships through fostering relationships with clinical, scientific, regulatory and marketing leaders worldwide.

Alexandra started her career as an academic cardiologist in Portugal and Spain and her past experience includes research in epidemiology and clinical trials in the Cardiovascular Department at the Brigham and Women's Hospital/ Harvard Medical School (HMS). She earned a Master in Medical Sciences from HMS and while working as a clinical cardiologist, she earned a doctorate degree (PhD). Her work was a driving force towards the refinement of the use of echocardiography in transcatheter structural heart interventions.

Alexandra is an internationally recognized thought leader with business acumen and an extensive record of multi-disciplinary medical collaborations, as educator, committee leader, author, and editor. She serves as Affiliate Professor of Medicine in Portugal and has been awarded several prizes, including the prestigious Senior Clinical Research and Career Development Award from HMS and Portuguese Foundation for Science and Technology



Dr Loreena HILL

Dr Loreena Hill worked as a heart failure nurse with prescribing authority for nearly 15 years in the Belfast Health & Social Care Trust.

Took up position as lecturer (teaching & research) 2018 in Queen's university, Belfast, within the School of Nursing & Midwifery, however continues to also work clinically.

Main research interest is Heart Failure (HF), in particular patients with advanced/palliative HF symptoms and those with an implanted device.

She currently coordinates two European projects, as well as supervises a number of regionally funded projects. In 2020 she was elected on to the Executive board of the HFA, where she also holds positions such as chair the Palliative Care Taskforce and Patient Liaison officer.



Prof. Friedrich KOEHLER

Prof. Friedrich Koehler, MD, FESC is Senior Physician in Cardiology at the Medical Department, Division of Cardiology and Angiology, Charité - Universitätsmedizin Berlin and Professor for Cardiovascular Telemedicine.

He is Director of the Centre for Cardiovascular Telemedicine which is specialized in research and development projects of remote patient management of heart failure patients.

From 2013-2018 he was Principal Investigator of the public funded randomized controlled trial „Telemedical Interventional Management in Heart Failure II“ (TIM-HF2, NCT01878630) with 1,538 heart failure patients.

Also, he is working in the Commission for Digital Transformation in Medicine of the German Society for Internal Medicine (DGIM).

Since 2019 he is consortium leader of the R&D project „TELEMED5000“, funded by the German Federal Ministry of Economic Affairs and Energy, focusing on artificial intelligence in remote patient management of cardiovascular patients.



Prof. Lars LUND

Prof. Lars H. Lund, MD PhD FESC FHA, is Professor of Medicine at Karolinska Institutet, and Senior Consultant at Karolinska University Hospital where he leads the heart failure research program. His expertise is heart failure phenotyping with a focus on ejection fraction, advanced heart failure therapy including devices and novel myotropes, and comparative outcomes studies as well as pragmatic registry-based trials.

He has leadership positions in heart failure registries, trials and observational cohorts. He is or has been Associate Editor for or on the Editorial Boards of numerous journals and has over 350 publications in peer reviewed journals, 22,000 citations, and an H-index of 69.



Prof. Theresa McDONAGH

Professor Theresa A McDonagh
MD, FRCP, FESC.
Consultant Cardiologist, and Clinical Lead for Cardiology and Heart Failure

Professor McDonagh qualified from the University of Edinburgh and completed her internal medicine training there. She trained in Cardiology at the Western Infirmary in Glasgow. Her main research was on the epidemiology of Left Ventricular Dysfunction and Natriuretic Peptides hormones.

Subsequently she was appointed as a Senior Lecturer at the University of Glasgow and Glasgow Royal Infirmary where she ran the Heart Failure Service and was the Cardiologist involved in the Heart Transplant Programme (1999-2004). Following this she was a Consultant Cardiologist at the Royal Brompton Hospital, London (2004-2011) where led the Heart Failure Service, before moving to King's College Hospital to head up the Heart Failure Programme.

Her main research interests are in novel biomarkers for heart failure and the delivery of heart failure services.

She is a past Chair of the British Society for Heart Failure a Past Chair of the Clinical Section of the Heart Failure Association of the European Society of Cardiology. She is the Clinical Lead for the National Heart Failure Audit.



Prof. Marco METRA

Prof. Marco Metra is full Professor of Cardiology, Director of the Institute of Cardiology of the Civil Hospitals and University of Brescia and Director of the Postgraduate School of Cardiology of the University of Brescia, Italy.

Marco Metra is co-chairman of the 2021 ESC guidelines for the diagnosis and treatment of heart failure. He is Editor-in-Chief of the European Journal of Heart Failure, 2019 impact factor 11.627, ranked 9th among 138 cardiology journals.

He is author of more than 700 PubMed listed scientific articles with a google-scholar calculated H-index of 107.

His areas of expertise : Treatment of heart failure and its comorbidities



Dr Clemens MITTMANN

Federal Institute for Drugs and Medical Devices (Germany)

Dr. Clemens Mittmann works at the Federal Institute for Drugs and Medical Devices (Germany), Department of Diabetes and Cardiovascular Diseases. He has been involved in cardiovascular procedures and the development of regulatory guidelines at the European Medicines Agency (EMA) as a clinical assessor, head of department and former core member of the Cardiovascular Working Party and present member of the Scientific Advice Working Party of the EMA.

Dr. Mittmann is board certified medical specialist in Clinical Pharmacology as well as in Pharmacology and Toxicology.

After finishing his medical studies in Germany and the USA, Dr. Mittmann graduated at the University of Munich, Germany. He completed Post Graduate studies in Molecular Biology at the University of Hamburg and his medical fellowship at the University Hospital of Hamburg, Germany (Cardiology/Pharmacology). He was Scholarship Holder and Research Awardee of the German Heart Foundation e.V.

Area of research: Signal transduction in heart failure and cardiovascular disease.



Prof. Wilfried MULLENS

Prof. Dr. Wilfried Mullens received his degree in Cardiology as well as Cardiac Rehabilitation in Belgium in 2005 and graduated as advanced fellow in Heart Failure and Cardiac Transplantation (2007) and Electrical Therapies for Heart Failure (2008) at the Cleveland Clinic, Ohio, United States of America.

He also received the Degree of Doctor of Philosophy (PhD) at the Technical University Eindhoven, the Netherlands in 2009.

Actually, he is working as a staff Cardiologist in the Hospital Oost-Limburg Genk, Belgium and also as Associate Professor in the School of Medicine and Life Sciences of University Hasselt, Belgium. He is Heart Failure clinician with a strong commitment to translational research translating new mechanistic insights into answering questions of clinical interest.

Main research topics are cardiac resynchronization therapy as well as the cardiorenal interactions with more than 250 peer reviewed publications.

He has been president of the Belgian Working Group on Heart Failure and serving as board member of European Heart Failure Association (HFA).



Prof. Uwe SIEBERT

Prof. Uwe Siebert, MD, MPH, MSc, ScD, Professor of Public Health, Medical Decision Making and Health Technology Assessment (HTA), is the Chair of the Department of Public Health, Health Services Research and HTA at UMIT - University for Health Sciences, Medical Informatics and Technology in Austria and the Director of the Division for HTA in the ONCOTYROL – Center for Personalized Cancer Medicine in Austria. He is also Adjunct Professor of Health Policy & Management, and Epidemiology, at the Harvard T.H. Chan School of Public Health and Affiliated Researcher of the Program on Cardiovascular Research at the Institute for Technology Assessment and Department of Radiology at the Massachusetts General Hospital, Harvard Medical School, Boston. He is the course director of the Harvard summer course on 'Decision Analysis in Clinical Research' and he has an adjunct teaching appointment at the School of Public Health & Epidemiology, University of Munich.

After medical school, he worked for several years as a physician in international public health projects in West-Africa, Brazil, and Germany. He then earned an MPH at the Munich School of Public Health, and completed an MSc in Epidemiology and a ScD in Health Policy and Management with a concentration in decision sciences at the Harvard School of Public Health. Before he started his faculty position at Harvard Medical School, he was the Director of the Bavarian Public Health Research and Coordinating Center at the University of Munich, Germany, and completed Visiting Scholarship at the Harvard Center for Risk Analysis.

His research interests include applying evidence-based quantitative and translational methods from public health, epidemiology, artificial intelligence, comparative effectiveness research, health services & outcomes research, economic evaluation, modeling, and health data & decision science in the framework of health care policy advice and HTA as well as in the clinical context of routine health care, public health policies and patient guidance.



His current substantive research focuses on cardiovascular disease, diabetes, cancer, neurological disorders, infectious diseases (e.g., COVID-19, hepatitis C, HPV, HIV), and others. His methodological research includes evaluations of public health interventions, prevention/screening, outbreak research, diagnostic imaging procedures, personalized medicine, non-pharmaceutical public health interventions, nature-based social prescribing, causal inference from “big” real world data and pragmatic trials, machine learning, decision modelling, and study designs controlling for treatment switching and noncompliance. He has been leading projects/work packages in several national and EU FP7 and H2020 projects (e.g., ELSA-GEN, BiomarCaRE, MedTechTA, DEXHELPP, EUthyroid, FORECEE, MDS-RIGHT, RECETAS, EUREGIO-EFH, CIDS, OnCoVID). He teaches courses in decision-analytic modeling, HTA, economic evaluation, analysis of big data, machine learning, and causal inference at several universities and for industry in Europe, USA, South America, and Asia.

Prof. Siebert is Past-President of the Society for Medical Decision Making (SMDM), a member of the Latin America Consortium Advisory Committee of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), member of the Committee for Cancer Screening and the Oncology Advisory Council of the Federal Ministry of Health in Austria, member of the Advisory Board of the GÖG - National Austrian Public Health Institute, member of the Working Group Public Health of the COVID-19 Future Operations Platform advising the Austrian government, member of the Austrian Cochrane Collaboration Branch, and a member of several national and international Directors Boards (Austrian Society of Epidemiology, German Network of EbM; German Association for Medical Informatics, Biometry and Epidemiology). He has served as Vice President of SMDM, and member of the ISPOR Board of Directors, the Society for Medical Decision Making Board of Trustees; the Harvard Flagship Initiative in Comparative Effectiveness Research, the ‘National HTA Strategy’ Expert Group of the Austrian Federal Ministry of Health, the Advisory Board of the Ludwig Boltzmann Institute for HTA in Austria, the International Expert Committee Advising the Institute for Quality and Efficiency in Health Care (IQWiG) on the Methods for Economic Evaluations of Health Care Interventions, the Directors Board of the German Competence Network Heart Failure, and the Extended Board of Directors of the German Association of Health Economics.

He is the Clinical Guideline Commissioner for the Association of the Scientific Medical Societies in Germany (AWMF), Authorized Expert in the COVID-19 Prognosis Consortium and the Scientific Platform Screening- and Monitoring Programs for COVID-19 of AGES - Austrian Agency for Health and Food Safety and GÖG advising the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection, member of the Task Force for COVID-19 Vaccination Implementation of the State Government Tyrol, Chair of the Horizontal Initiative in Causal Inference of the German Society for Epidemiology (DGEpi), Chair of the Working Group “Effectiveness and Side Effects of Non-Pharmaceutical Interventions” of the Competence Network for Public Health for COVID-19, and Chair of the Working Groups ‘Health Economics’ and ‘Medical Decision Making’ of the German Society for Medical Informatics, Biometry and Epidemiology (GMDS). He is Co-Chair of the ISPOR-SMDM Modeling Good Research Practices Task Force, Co-Chair of the ‘Issues in Methodology Section’ of the SMDM Policy Initiative, a Leadership Member of the ISPOR Personalized/Precision Medicine Special Interest Group, and member of the SMDM COVID-19 Modeling Special Committee.



He has worked with several HTA Agencies (e.g., DAHTA@DIMDI/Germany, IQWiG/Germany, NICE/UK, ANVISA/Brazil, IATS/Brazil, AHRQ/USA, CADTH/Canada, LBI-HTA/Austria, GÖG/Austria) and he advises public and government agencies, academic institutions and industry regarding the conduction of HTAs and their impact on policy and reimbursement decisions. He has authored more than 400 publications (> 20,000 citations, H index > 50) including HTA reports, textbook chapters, scientific articles, policy briefs and editorials, and is Editor of the European Journal of Epidemiology, Associate Editor of Public Health Reviews as well as editorial board member of several scientific journals.



Prof. Scott SOLOMON

Prof. Scott Solomon, MD is the Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women's Hospital. He received his A.B. from Williams College and his M.D. from Harvard Medical School.

Dr. Solomon's research interests have focused on changes in ventricular structure and function following myocardial injury, modifiers of risk and influences of outcome in patients following myocardial infarction and with chronic heart failure, cardiovascular safety of non-cardiovascular therapies, factors that influence the transition from hypertension to heart failure, and heart failure with preserved ejection fraction. He has pioneered the use of cardiac imaging in cardiovascular drug and device development and use of imaging in clinical trials.

He is an expert in cardiovascular safety and outcomes research, and led the NIH-sponsored Celecoxib Cross-trials Safety Study which directly informed regulatory agencies about the safety of widely used non-steroidal anti-inflammatory agents.

He and his research group have played a leading role in the development of several heart failure therapeutics, through phase 2 and phase 3 international clinical trials in heart failure, hypertension and myocardial infarction, including the SAVE, HEART, VALIANT, CHARM, PEACE, OVERTURE, MADITCRT, ALOFT, ALLAY, TREAT, RED-HF, ALTITUDE, FREEDOM, TOPCAT, ASTRONAUT, ATMOSPHERE, COSMIC, APOLLO, PARADIGM, PARAGON, DAPA-HF, EXPLORER-HCM, GALACTIC HF trials.

He directs the Cardiac Imaging Core Laboratory and the Clinical Trials Endpoints Center at Brigham and Women's Hospital. He directed the Cardiac Imaging Center for the NHLBI Atherosclerosis Risk in Communities (ARIC) study and Hispanic Community Health Study – Study of Latinos (HCHS-SOL), the two largest NIH cohort studies. He served as PI for the NHLBI funded INVESTED trial studying influenza vaccine to reduce cardiovascular events.



A particular research focus has been understanding the epidemiology, pathophysiology, and outcomes in heart failure with preserved and mildly reduced ejection fraction, and testing new therapies for these conditions. He led the first positive Phase II trial in HFpEF, and the PARAGON-HF, DELIVER and FINEARTS outcomes trials in heart failure with preserved and mildly reduced ejection fraction.

His work with sacubitril/valsartan in this population led to the first FDA indication for a therapy for heart failure with ejection fraction > 40%.

Dr. Solomon leads a research group consisting of 8 faculty members, 8 research fellows and 40 support staff. He currently receives, or has received, extensive research support from the NIH and multiple industry sponsors. He has directed the Harvard Medical School Cardiovascular Clerkship and the Echocardiography training program at Brigham and Women's Hospital.

He has authored more than 700 peer-reviewed articles, reviews and editorials, three textbooks of cardiac imaging, including Essential Echocardiography, A Companion to Braunwald's Heart

Disease (2018), and the Echocardiography sections for the 10th and 11th edition of Braunwald's Heart Disease and 19th and 20th edition Harrison's Principles of Internal Medicine.

He is listed by Thomson-Reuters as one of the most highly cited scientists for the past 5 years. He has received a Doctor Honoris Causa (honorary doctorate) from Semmelweis University in Budapest, Hungary.

He has served as Cardiology Section Editor at UpToDate, Associate Editor at Circulation, International Associate Editor at the European Heart Journal, and currently serves as editor for the 12th Edition of Braunwald's Heart Disease.



Prof. Maurizio VOLTERRANI

Professor Maurizio Volterrani, MD, PhD, FHFA - IRCCS San Raffaele of Rome – Research Hospital Full Professor in Science Movement

Prof. Maurizio Volterrani is Head of the Cardiac Pulmonary Department at IRCCS San Raffaele in Rome.

He is full professor in Science Movement at the Department of Human Science and Promotion of Quality Life at the San Raffaele Telematic University of Rome as well as holding a full professorship in sport science and an associate professorship in cardiovascular and respiratory medicine.

Prof. Volterrani's main research interests include heart failure, exercise training in cardiac rehabilitation, telemedicine, hyperkalaemia and kidney failure.

He is and has been principal investigator in multiple international clinical trials mainly related to heart failure.

He is a board member as well as Fellow of the Heart Failure Association (HFA) of the European Society of Cardiology and holds the following positions:

- coordinator the Exercise Physiology and Training Committee of the HFA
- coordinator of Endorsement Committee for Higher Educatio of the HFA
- co-coordinator of the Registry and Epidemiology Committee of the HFA
- co-coordinator of the Digital Health Committee of the HFA
- Member of the HFA Study Group on Cachexia, Sarcopenia and Frailty
- Liaison Officer for the ESC Patient Forum
- Ex-officio Member of the Council on Stroke

Prof. Volterrani is also member of the Italian Ministry of Health Commission for IRCCS Research Hospitals Cardiology Network and is an expert in the Scientific Advisor Group for the European Medicines Agency.



Finally, Prof. Volterrani is Editor of the Monaldi Archive for Chest Diseases, Associate Editor for the European Journal of Heart Failure and ESC Heart Failure Journal. He has authored over 280 publications in national and international scientific journals with a current H-index of 48.